Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15061703 | 1.00 | CHRM4 (0.33) | CHRM4CHRM5CHRM1CHRM3CNR2 | |
| SCHEMBL21890737 | 0.84 | PPM1D (0.31) | — | |
| SCHEMBL27993185 | 0.79 | — | — | |
| SCHEMBL13166986 | 0.79 | ATM (0.34) | — | |
| SCHEMBL21704247 | 0.78 | — | — | |
| SCHEMBL31057204 | 0.76 | PPM1D (0.32) | ALDH1A1 | |
| SCHEMBL31057446 | 0.76 | TP53 (0.32) | ALDH1A1CYP1A2 | |
| SCHEMBL31057255 | 0.76 | TP53 (0.32) | ALDH1A1CYP1A2 | |
| SCHEMBL31057398 | 0.76 | TP53 (0.32) | ALDH1A1CYP1A2 | |
| SCHEMBL2887683 | 0.76 | PPM1D (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3882247-A1 | SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-09-22 | — | — | EP | disclosed |
| EP-3542789-A2 | LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN-CODING RNA | GlaxoSmithKline Biologicals SA (BE) | 2019-09-25 | — | — | EP | disclosed |
| EP-2611420-B1 | LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN-CODING RNA | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2019-03-27 | — | — | EP | disclosed |
| US-9301923-B2 | Lipids, lipid compositions, and methods of using them | NOVARTIS AG (CH) | 2016-04-05 | — | — | US | disclosed |
| US-9301923-B2 | Lipids, lipid compositions, and methods of using them | NOVARTIS AG (CH) | 2016-04-05 | — | — | US | disclosed |
| US-20140309277-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140309277-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20130189351-A1 | LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN CODING RNA | NOVARTIS AG (CH) | 2013-07-25 | — | — | US | disclosed |
| US-20130189351-A1 | LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN CODING RNA | NOVARTIS AG (CH) | 2013-07-25 | — | — | US | disclosed |
| US-20110200582-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200582-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | SGMS1, SGMS2, LIPC | CHRM4 4802/4885CHRM5 4775/4885CHRM1 4792/4885 |
| US-20130189351-A1 | LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN CODING RNA | NSUN3, RNMT, AGO2 | CHRM4 4780/4885CHRM5 4837/4885CHRM1 4806/4885 |
| US-20140309277-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | SGMS1, SGMS2, LIPC | CHRM4 4802/4885CHRM5 4775/4885CHRM1 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.